AVALO THERAPEUTICS, INC. Shareholders' Equity
AVALO THERAPEUTICS, INC. (AVTX) had Shareholders' Equity of $448.66 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $448.66M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $68.32M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $83.05M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $91.55M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $448.66M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $68.32M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $83.05M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $91.55M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $104.57M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $122.61M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $133.03M 10-Q · filed 2026-08-06 | |
| 2024-09-30 | $21.08M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | -$13.61M 10-Q · filed 2025-11-06 | |
| 2024-03-31 | -$112.54M 10-Q · filed 2025-08-07 | |
| 2023-12-31 | $7.30M 10-K · filed 2026-03-23 | |
| 2023-09-30 | $14.70M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$6.97M 10-Q · filed 2024-11-07 | |
| 2023-03-31 | -$6.27M 10-Q · filed 2024-08-12 | |
| 2022-12-31 | -$10.91M 10-K · filed 2025-03-20 | |
| 2022-09-30 | -$2.03M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | -$5.95M 10-Q · filed 2023-11-09 | |
| 2022-03-31 | $6.34M 10-Q · filed 2023-08-03 | $6.34M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $23.08M 10-K · filed 2024-03-29 | |
| 2021-09-30 | $40.31M 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $21.59M 10-Q · filed 2022-11-07 | |
| 2021-03-31 | $33.16M 10-Q · filed 2022-08-04 | |
| 2020-12-31 | $24.56M 10-K · filed 2023-03-29 | $24.56M 10-K · filed 2021-03-08 |
| 2020-09-30 | $38.57M 10-Q · filed 2021-11-09 | $38.57M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $50.58M 10-Q · filed 2021-11-09 | $50.58M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $25.59M 10-Q · filed 2021-08-02 | $25.59M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $21.00M 10-K · filed 2022-03-02 | $21.00M 10-K · filed 2020-03-11 |
| 2019-09-30 | $18.22M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $17.70M 10-Q · filed 2020-11-09 | |
| 2019-03-31 | $23.12M 10-Q · filed 2020-08-06 | |
| 2018-12-31 | $20.91M 10-K · filed 2021-03-08 | |
| 2018-09-30 | $19.51M 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $19.22M 10-Q · filed 2019-11-14 | $19.22M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $24.58M 10-Q · filed 2019-08-08 | $24.58M 10-Q · filed 2018-05-11 |
| 2017-12-31 | $27.86M 10-K · filed 2020-03-11 | |
| 2017-09-30 | $22.12M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $3.14M 10-Q · filed 2017-08-14 | |
| 2017-03-31 | -$425.76K 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $207.00K 10-K · filed 2019-03-18 | |
| 2016-09-30 | $586.83K 10-Q · filed 2016-11-08 | |
| 2016-06-30 | $5.57M 10-Q · filed 2016-08-15 | |
| 2016-03-31 | $8.88M 10-Q · filed 2016-05-16 | |
| 2015-12-31 | $13.08M 10-K · filed 2018-04-02 | |
| 2015-09-30 | -$32.85M 10-Q · filed 2015-11-13 | |
| 2014-12-31 | -$26.33M 10-K · filed 2018-04-02 | |
| 2013-12-31 | -$17.85M 10-K · filed 2017-03-14 | |
| 2012-12-31 | -$11.38M 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |